Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 24;11:556104. doi: 10.3389/fneur.2020.556104

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Nowak, Muppidi, Beydoun, O'Brien, Yountz, Howard and for the REGAIN study group.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.>

PMC Copyright notice

Immunosuppressive therapy (IST) doses at open-label extension (OLE) baseline and last assessment in patients using (A) prednisone and related corticosteroids (PRED; n = 90), (B) azathioprine (AZA; n = 39), or (C) mycophenolate mofetil (MMF; n = 30) at OLE baseline. A total of 90 patients were using PRED at OLE baseline, 39 were using AZA, and 30 were using MMF. The distribution of IST doses at OLE baseline and last assessment, mean and median daily doses at OLE baseline and last assessment, and mean and median dose reductions from OLE baseline to last assessment are shown for these patients. P-values for mean percentage changes were calculated using the one-sample t-test; P-values for median percentage changes were calculated using the Wilcoxon signed-rank test. SD, standard deviation.